Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI

Trial Profile

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction After Acute MI

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Firibastat (Primary) ; Ramipril
  • Indications Heart failure; Left ventricular dysfunction; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms QUORUM
  • Sponsors Quantum Genomics
  • Most Recent Events

    • 03 Oct 2019 According to a Quantum Genomics media release, this study has an estimated overall cost of 8 million Euro and results are expected in the second half of 2020.
    • 06 Jun 2019 According to a Quantum Genomics media release, the first patient has been enrolled in this study.
    • 06 Jun 2019 Status changed from not yet recruiting to recruiting, according to a Quantum Genomics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top